SEC For	m 4 FORM	4	UNITED S	TATE	ES SE	ECUR	ITIE	ES AND	ЕХСНА	NGE C	оммі	SSION						
						Washington, D.C. 20549									OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ursuant	to Section	n 16(a	ES IN BE a) of the Secu Investment C	irities Exchar	ige Act of 1		SHIP	Estima	Number ated ave per res	erage burden	235-0287 0.5		
1. Name and Address of Reporting Person* Booth Bruce					2. Issuer Name and Ticker or Trading Symbol <u>Kymera Therapeutics, Inc.</u> [KYMR]							Relationship o eck all applio X Directo	cable)	Reporting Person(s) to Issuer lle) 10% Owne				
(Last) (First) (Middle) C/O KYMERA THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/16/2021							Officer below)			Other (s below)	becify		
200 ARSENAL YARDS BLVD., SUITE 230				4	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Ir								Individual or Joint/Group Filing (Check Applicable ne)					
(Street) WATERTOWN MA 02472												X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																		
		Tab	ole I - Non-D	erivati	ve Se	curities	s Ac	quired, D	isposed c	of, or Be	neficial	ly Owned						
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				te	Execution			, Transaction Disposed Code (Instr. 5)		ities Acquire d Of (D) (Ins		Beneficia Owned F	es ally following	Form:	Direct C Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Price Reported Transaction (Instr. 3 and				(Instr. 4)		
		-	Table II - De (e.ç					uired, Dis , options				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	, 4. Trans	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$49.1	06/16/2021		A		20,063		(1)	06/15/2031	Common Stock	20,063	\$0.00	20,063	3	D ⁽²⁾			

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders.

2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Remarks:

/s/ Ommer Chohan, as Attorney-in-Fact

Date

06/17/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.